MZLMarginal Zone Lymphoma
MZLManizales, Colombia - Santaguida (Airport Code)
MZLMantle Zone Lymphoma (medical illness)
MZLMinimum Zone Line (see LSZ)
MZLMeyer Zall Laboratories, Pty. Ltd. (est. 1992; South Africa)
References in periodicals archive ?
If the B cells and the plasma cells are part of the same clone, the diagnosis of lymphoplasmacytic lymphoma or MZL is warranted.
To avoid the possibility that the 2 populations were part of the same clone, we did not select cases of DLBCL arising from FL or MZL, with the exception of one case, in which, in addition to FL and DLBCL, there also was a CD5+, clonal B-cell population.
The most likely diagnosis is MZL, but PTLD has not been completely ruled out.
It was fear of Muslim domination that pulled together the various ethnic associations among northerners to form the NML, the MZL, the UMBC, and others.
A time series plot of MZL, plotted by date of capture, shows an increasing trend reflecting the growth that postsmolts experience during early marine residence (Fig.
A careful review of immunophenotype of the B cells and immunohistochemical staining for CD56 and/or cyclin D1 to identify abnormal plasma cells will allow separation from conditions such as LPL, splenic MZL, and CLL with plasmacytic differentiation.
The differential diagnosis includes mantle cell lymphoma, CLL/SLL, MZL, and plasma cell myeloma.
MZL almost exclusively affects adults, although rare cases in younger patients have been reported.
A recent study found that many MZLs involving orbital soft tissue lack key features associated with MALT-type MZL (eg, lack of lymphoepithelial lesions) and suggests avoiding the designation "MALT lymphoma" in the diagnosis.
Patients with nodal MZL present with lymphadenopathy without evidence of extranodal involvement or without involvement of mucosa-associated lymphoid tissue (MALT).
Overview of B-cell NHL, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines for DLBCL, FL, MZL and MCL.
Of 19 MCL patients, 13 (68%) achieved a response, including one complete response; four of 13 patients with FL (28%) experienced a response; of 18 DLBCL patients, five (28%) achieved a response with one patient experiencing a complete response; three of four WM patients (75%) achieved a response and two of three MZL patients (67%) achieved a response with ABT-199/GDC-0199 as a monotherapy.